BridgeBio Oncology Therapeutics, In (BBOT) PT Lowered to $25 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts BBOT Hot Sheet
Price: $2.27 -1.3%
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
10 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
JPMorgan analyst Priyanka Grover lowered the price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) to $25.00 (from $27.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Modine Manufacturing (MOD) PT Lowered to $178 at Cantor Fitzgerald
- Pinnacle West Capital (PNW) PT Raised to $108 at BMO Capital
- Procore Technologies, Inc (PCOR) PT Raised to $86 at BMO Capital on 'Impressive Execution'
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
